Drug Trial Radar · NCT06531707
Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Jun 24, 2024
Primary completion
Jan 20, 2025
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the drug combination of Ibuprofen/Loratadine versus Ibuprofen versus Loratadine as monotherapy for the symptomatic treatment of the common cold.
Conditions
- Common Cold
Interventions
Ibuprofen + Loratadine fixed doseDrug
Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
IbuprofenDrug
Suspension 2,000 mg / 100 mL, 20 mL twice a day
LoratadineDrug
Suspension 1 mg / 1 mL, 5 mL twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the improvement in symptoms, comparing the percentage change through the Jackson scoreTime frame: 7 days
- Number of participants with treatment-related adverse events through the patient's diary record, by treatment groupTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laboratorio Silanes, S.A. de C.V.
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.